Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab

Gerald Steven Falchook • 5 Jun 2022
ASCO 2022
General Cobolimab Dostarlimab
AMBER

Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, discusses results of the multi-center, open-label Phase I AMBER (NCT02817633) trial investigating the TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab. Primary endpoints were safety, tolerability, and recommended Phase II dose. 104 patients were included in the trial. The most common cancers were non-small cell lung cancer (NSCLC), skin, and peritoneal mesothelioma. Results demonstrated cobolimab plus dostarlimab were well tolerated and exhibited preliminary antitumor activity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Gerald Steven Falchook

B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6
0:44
B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6
Gerald Steven Falchook • 5 Jun 2022

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals